CoChat

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1

Open access
Arnault, Jean Philippe, Mateus, Christine, Escudier, Bernard, Tomasic, Gorana, Wechsler, Janine, Hollville, Emilie, Soria, Jean-Charles, Malka, David, Sarasin, Alain, Larcher, Magalie, André, Jocelyne, Kamsu-Kom, Nyam, Boussemart, Lise, Lacroix, Ludovic, Spatz, Alain, Eggermont, Alexander M., Druillennec, Sabine, Vagner, Stephan, Eychène, Alain, Dumaz, Nicolas, Robert, Caroline · 2012 · Clinical Cancer Research
Cited by 123

The DOI matches its Crossref record.

Abstract

Purpose: The emergence of skin tumors in patients treated with sorafenib or with more recent BRAF inhibitors is an intriguing and potentially serious event. We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib. Experimental Design: Thirty-one skin lesions from patients receiving sorafenib were characterized clinically and pathologically. DNA extracted from the lesions was screened for mutation hot spots of HRAS, NRAS, KiRAS, TP53, EGFR, BRAF, AKT1, PI3KCA, TGFBR1, and PTEN. Biological effect of sorafenib was studied in vivo in normal skin specimen and in vitro on cultured keratinocytes. Results: We observed a continuous spectrum of lesions: from benign to more inflammatory and proliferative lesions, all seemingly initiated in the hair follicles. Eight oncogenic HRAS, TGFBR1, and TP53 mutations were found in 2 benign lesions, 3 keratoacanthomas (KA) and 3 KA-like squamous cell carcinoma (SCC). Six of them correspond to the typical UV signature. Treatment with sorafenib led to an increased keratinocyte proliferation and a tendency toward increased mitogen-activated protein kinase (MAPK) pathway activation in normal skin. Sorafenib induced BRAF–CRAF dimerization in cultured keratinocytes and activated CRAF with a dose-dependent effect on MAP-kinase pathway activation and on keratinocyte proliferation. Conclusion: Sorafenib induces keratinocyte proliferation in vivo and a time- and dose-dependent activation of the MAP kinase pathway in vitro. It is associated with a spectrum of lesions ranging from benign follicular cystic lesions to KA-like SCC. Additional and potentially preexisting somatic genetic events, like UV-induced mutations, might influence the evolution of benign lesions to more proliferative and malignant tumors. Clin Cancer Res; 18(1); 263–72. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-1344

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 123

Metadata

Authors
Arnault, J. P., Mateus, C., Escudier, B., Tomasic, G., Wechsler, J., Hollville, E., Soria, J.-C., Malka, D., Sarasin, A., Larcher, M., André, J., Kamsu-Kom, N., Boussemart, L., Lacroix, L., Spatz, A., Eggermont, A. M., Druillennec, S., Vagner, S., Eychène, A., Dumaz, N., & Robert, C.
Venue
Clinical Cancer Research
Published
2012-01-01
Volume
18
Issue
1
Pages
263-272
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2112967018
Cited by
123
References
0
FWCI
24.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1344
The paper
Arnault, J. P., Mateus, C., Escudier, B., Tomasic, G., Wechsler, J., Hollville, E., Soria, J.-C., Malka, D., Sarasin, A., Larcher, M., André, J., Kamsu-Kom, N., Boussemart, L., Lacroix, L., Spatz, A., Eggermont, A. M., Druillennec, S., Vagner, S., Eychène, A., . . . Robert, C. (2012). Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.